FTH — Faeth Therapeutics, Share News
0.000.00%
Last trade - 00:00- $459.38m
- $256.60m
Brief: Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron For Phase 1/2 Clinical Trial Evaluating SNS-101
Brief: Sensei Biotherapeutics Provides Update On Strategic Priorities
Brief: Sensei Biotherapeutics Announces Collaboration With Washington University, St. Louis To Support Development Of SNS-101
Brief: Major Investor In Sensei Biotherapeutics Urges Board To Seek Shareholder Mandate
Sensei Biotherapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Sensei Biotherapeutics Reports Q3 Results
Sensei Biotherapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics Presents Preclinical Data For SNS-101 At The Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference
Brief: Sensei Biotherapeutics To Present Preclinical Data For SNS-101
Brief: Sensei Announces New Preclinical Data For SNS-101
Sensei Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results
Sensei Biotherapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Apeiron Investment Group Ltd Reports 11.2% Stake In Sensei Biotherapeutics
Brief: Sensei Biotherapeutics Appoints Patrick Gallagher As Chief Business Officer
Sensei Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Sensei Biotherapeutics Reports First Quarter 2022 Financial Results And Recent Business Highlights
Sensei Biotherapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Sensei Biotherapeutics Files For Mixed Shelf Of Upto $150 Million